FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1752550900> ?p ?o ?g. }

• W1752550900 abstract "Epilepsy is a common neurological condition, with an estimated incidence of 50 per 100,000 persons. People with epilepsy may present with various types of immunological abnormalities, such as low serum immunoglobulin A (IgA) levels, lack of the immunoglobulin G (IgG) subclass and identification of certain types of antibodies. Intravenous immunoglobulin (IVIg) treatment may represent a valuable approach and its efficacy has important implications for epilepsy management. This is an updated version of the original Cochrane review published in Issue 1, 2011.To examine the effects of IVIg on the frequency and duration of seizures, quality of life and adverse effects when used as monotherapy or as add-on treatment for people with epilepsy.For the latest update, we searched the Cochrane Epilepsy Group Specialized Register (2 February 2017), the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (2 February 2017), MEDLINE (Ovid, 1946 to 2 February 2017), Web of Science (1898 to 2 February 2017), ISRCTN registry (2 February 2017), WHO International Clinical Trials Registry Platform (ICTRP, 2 February 2017), the US National Institutes of Health ClinicalTrials.gov (2 February 2017), and reference lists of articles.Randomized or quasi-randomized controlled trials of IVIg as monotherapy or add-on treatment in people with epilepsy.Two review authors independently assessed the trials for inclusion and extracted data. We contacted study authors for additional information. Outcomes included percentage of people rendered seizure-free, 50% or greater reduction in seizure frequency, adverse effects, treatment withdrawal and quality of life.We included one study (61 participants). The included study was a randomized, double-blind, placebo-controlled, multi-centre trial which compared the treatment efficacy of IVIg as an add-on with a placebo add-on in patients with refractory epilepsy. There was no significant difference between IVIg and placebo in 50% or greater reduction in seizure frequency. The study reported a statistically significant effect for global assessment in favour of IVIg. No adverse effects were demonstrated. We found no randomized controlled trials that investigated the effects of IVIg monotherapy for epilepsy. Overall, the included study was rated as low/unclear risk of bias. Using GRADE methodology, the quality of the evidence was rated as low.We cannot draw any reliable conclusions regarding the efficacy of IVIg as a treatment for epilepsy. Further randomized controlled trials are needed." @default.
• W1752550900 created "2016-06-24" @default.
• W1752550900 creator A5010379826 @default.
• W1752550900 creator A5034157866 @default.
• W1752550900 creator A5042945387 @default.
• W1752550900 creator A5043349161 @default.
• W1752550900 creator A5046154346 @default.
• W1752550900 creator A5068930687 @default.
• W1752550900 creator A5069011107 @default.
• W1752550900 date "2011-01-19" @default.
• W1752550900 modified "2023-10-01" @default.
• W1752550900 title "Intravenous immunoglobulins for epilepsy" @default.
• W1752550900 cites W1598602811 @default.
• W1752550900 cites W1752550900 @default.
• W1752550900 cites W1849670650 @default.
• W1752550900 cites W1967986271 @default.
• W1752550900 cites W1972489874 @default.
• W1752550900 cites W1987833455 @default.
• W1752550900 cites W2013566590 @default.
• W1752550900 cites W2014191362 @default.
• W1752550900 cites W2019422498 @default.
• W1752550900 cites W2026830381 @default.
• W1752550900 cites W2042528152 @default.
• W1752550900 cites W2043631683 @default.
• W1752550900 cites W2050502246 @default.
• W1752550900 cites W2058034539 @default.
• W1752550900 cites W2059170893 @default.
• W1752550900 cites W2074707827 @default.
• W1752550900 cites W2076993158 @default.
• W1752550900 cites W2081689918 @default.
• W1752550900 cites W2087683393 @default.
• W1752550900 cites W2090862610 @default.
• W1752550900 cites W2094613412 @default.
• W1752550900 cites W2103024352 @default.
• W1752550900 cites W2107464979 @default.
• W1752550900 cites W2108696783 @default.
• W1752550900 cites W2108725527 @default.
• W1752550900 cites W2136403658 @default.
• W1752550900 cites W2144996528 @default.
• W1752550900 cites W2145664048 @default.
• W1752550900 cites W2153561647 @default.
• W1752550900 cites W2169105242 @default.
• W1752550900 cites W22147787 @default.
• W1752550900 cites W2401418177 @default.
• W1752550900 cites W2402305620 @default.
• W1752550900 cites W2409620397 @default.
• W1752550900 cites W2413334430 @default.
• W1752550900 cites W2460177253 @default.
• W1752550900 cites W2471485442 @default.
• W1752550900 cites W3140091027 @default.
• W1752550900 cites W4252468176 @default.
• W1752550900 cites W28827032 @default.
• W1752550900 doi "https://doi.org/10.1002/14651858.cd008557.pub2" @default.
• W1752550900 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6887830" @default.
• W1752550900 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31792946" @default.
• W1752550900 hasPublicationYear "2011" @default.
• W1752550900 type Work @default.
• W1752550900 sameAs 1752550900 @default.
• W1752550900 citedByCount "16" @default.
• W1752550900 countsByYear W17525509002013 @default.
• W1752550900 countsByYear W17525509002017 @default.
• W1752550900 countsByYear W17525509002018 @default.
• W1752550900 countsByYear W17525509002019 @default.
• W1752550900 countsByYear W17525509002020 @default.
• W1752550900 countsByYear W17525509002021 @default.
• W1752550900 crossrefType "reference-entry" @default.
• W1752550900 hasAuthorship W1752550900A5010379826 @default.
• W1752550900 hasAuthorship W1752550900A5034157866 @default.
• W1752550900 hasAuthorship W1752550900A5042945387 @default.
• W1752550900 hasAuthorship W1752550900A5043349161 @default.
• W1752550900 hasAuthorship W1752550900A5046154346 @default.
• W1752550900 hasAuthorship W1752550900A5068930687 @default.
• W1752550900 hasAuthorship W1752550900A5069011107 @default.
• W1752550900 hasConcept C118552586 @default.
• W1752550900 hasConcept C126322002 @default.
• W1752550900 hasConcept C168563851 @default.
• W1752550900 hasConcept C187212893 @default.
• W1752550900 hasConcept C197934379 @default.
• W1752550900 hasConcept C2778186239 @default.
• W1752550900 hasConcept C535046627 @default.
• W1752550900 hasConcept C71924100 @default.
• W1752550900 hasConcept C95190672 @default.
• W1752550900 hasConceptScore W1752550900C118552586 @default.
• W1752550900 hasConceptScore W1752550900C126322002 @default.
• W1752550900 hasConceptScore W1752550900C168563851 @default.
• W1752550900 hasConceptScore W1752550900C187212893 @default.
• W1752550900 hasConceptScore W1752550900C197934379 @default.
• W1752550900 hasConceptScore W1752550900C2778186239 @default.
• W1752550900 hasConceptScore W1752550900C535046627 @default.
• W1752550900 hasConceptScore W1752550900C71924100 @default.
• W1752550900 hasConceptScore W1752550900C95190672 @default.
• W1752550900 hasLocation W17525509001 @default.
• W1752550900 hasLocation W17525509002 @default.
• W1752550900 hasOpenAccess W1752550900 @default.
• W1752550900 hasPrimaryLocation W17525509001 @default.
• W1752550900 hasRelatedWork W2914141471 @default.
• W1752550900 hasRelatedWork W3028296069 @default.
• W1752550900 hasRelatedWork W3036269150 @default.
• W1752550900 hasRelatedWork W3159250744 @default.
• W1752550900 hasRelatedWork W3213188346 @default.

• next